T Cells in Multiple Myeloma: Is This a Reliable Population to Count on as Antitumor Effector Cells?

References

• Boccadoro M., Pileri A. Standard chemotherapy for myelomatosis: an area of great controversy. Hematol. Oncol. Clin. N. Am. 1992; 6: 371–382
   PubMed Web of Science ®Google Scholar
• Alexanian R., Haut A., Khan A.U., Lane M., McKelvey E.M., Migliore P.J., Stuckey W.J., Wilson E.M. Treatment of multiple myeloma: combination chemotherapy with different melphalan dose regimens. JAMA 1969; 208: 1680–1685
   PubMed Web of Science ®Google Scholar
• Mandelli F., Avvisati G., Amadori S., Boccadoro M., Gernone A., Lauta V.M., Marmont F., Petrucci M.T., Tribalto M., Vegna M.L., Dammacco F., Pileri A. Maintenance treatment with alpha-2b recombinant interferon significantly improves response and survival duration in multiple myeloma patients responding to conventional induction chemotherapy. N. Engl. J. Med. 1990; 322: 1430–1434
   PubMed Web of Science ®Google Scholar
• Hoover R.G., Kornbluth J. Immunoregulation of murine and human myeloma. Hematol. Oncol. Clin. N. Am. 1992; 6: 407–424
   PubMed Web of Science ®Google Scholar
• Kyle R.A. Long-term survival in multiple myeloma. N. Engl. J. Med. 1983; 308: 314–316
   PubMed Web of Science ®Google Scholar
• Alexanian R., Gehan E., Haut A., Saiki J., Weick J. Unmaintained remissions in multiple myeloma. Blood 1978; 51: 1005–1011
   PubMed Web of Science ®Google Scholar
• Joshua D.E., Wearne A., Kronenberg H. Immunoregulation and prognosis in myeloma. Lancet 1987; ii: 251–253
   Google Scholar
• Lea T., Forre O.T., Michaelsen T.E., Natvig J.B. Shared idiotypes on human peripheral blood B and T lymphocytes. J. Immunol. 1979; 122: 2413–2417
   PubMed Web of Science ®Google Scholar
• Preud'homme J.L., Klein M., LaBaume S., Seligman M. Idiotype-bearing and antigen-binding receptors produced by blood T lymphocytes in a case of human myeloma. Eur. J. Immunol. 1977; 7: 840–844
   PubMed Web of Science ®Google Scholar
• Moller G. Idiotypes on T and B cells. Immunol. Rev. 1977; 34: 1–164
   Google Scholar
• Hoover R.C., Hickman S., Gebel H.M., Rebbe N., Lynch R.G. Expansion of Fc Receptor-bearing T lymphocytes in patients with immunoglobulin G and immunoglobulin A myeloma. J. Clin, invest. 1981; 67: 308–311
   PubMed Web of Science ®Google Scholar
• Berenson J., Lichtenstein A. Clonal rearrangement of the beta-T cell receptor gene in multiple myeloma. Leukemia 1989; 3: 133–136
   PubMed Web of Science ®Google Scholar
• Dianzani U., Pileri A., Boccadoro M., Palumbo A., Pioppo P., Bianchi A., Camponi A., Battaglio S., Massaia M. Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status. Blood 1988; 72: 1064–1068
   PubMed Web of Science ®Google Scholar
• Wen T., Mellstedt H., Jondal M. Presence of clonal T cell populations in chronic B lymphocytic leukemia and smoldering myeloma. J. Exp. Med. 1990; 171: 659–666
   PubMed Web of Science ®Google Scholar
• Janson C.H., Grunewald J., Osterborg A., Der Simonian H., Brenner M.B., Mellstedt H., Wigzell H. Predominant T cell receptor V gene usage in patients with abnormal clones of B cells. Blood 1991; 77: 1776–1780
   PubMed Web of Science ®Google Scholar
• Holm G., Bergenbrant S., Lefvert A.K., Yi Q., Osterborg A., Mellstedt H. Anti-idiotypic immunity as a potential regulator in myeloma and related diseases. Ann. NY Acad. Sci. 1992; 636: 178–183
   Web of Science ®Google Scholar
• Osterborg A., Masucci M., Bergenbrant S., Holm G., Lefvert A.K., Mellstedt H. Generation of T cell clones binding F(ab')2 fragments of the idiotypic immunoglobulin in patients with monclonal gammopathy. Cancer Immunol. Immunother. 1991; 34: 157–162
   PubMed Web of Science ®Google Scholar
• Massaia M., Dianzani U., Bianchi A., Camponi A., Boccadoro M., Pileri A. Defective generation of alloreactive cytotoxic T lymphocytes (CTL) in human monoclonal gammopathies. Clin. Exp. Immunol. 1988; 73: 214–218
   PubMed Web of Science ®Google Scholar
• Massaia M., Bianchi A., Dianzani U., Camponi A., Attisano C., Boccadoro M., Pileri A. Defective interleukin-2 induction of lymphokine-activated killer (LAK) activity in peripheral blood T lymphocytes of patients with monoclonal gammopathies. Clin. Exp. Immunol. 1989; 79: 100–104
   Web of Science ®Google Scholar
• Boccadoro M., Omede P., Massaia M., Dianzani U., Pioppo P., Battaglio S., Meregalli M., Pileri A. Human myeloma: several subsets of circulating lymphocytes express plasma cell-associated antigens. Eur. J. Haematol. 1988; 40: 299–304
   PubMed Web of Science ®Google Scholar
• Omede P., Boccadoro M., Gallone G., Frieri R., Battaglio S., Redoglia V., Pileri A. Multiple myeloma: increased circulating lymphocytes carrying plasma cell-associated antigens as an indicator of poor survival. Blood 1990; 76: 1375–1379
   PubMed Web of Science ®Google Scholar
• Massaia M., Dianzani U., Bianchi A., Camponi A., Boccadoro M., Pileri A. Immune dysregulation in monoclonal gammopathies. Bone Marrow Transplant 1989; 4(suppl 1)165–167
   PubMedGoogle Scholar
• Massaia M., Ma D. D. F., Boccadoro M., Golzio F., Gavarotti P., Dianzani U., Pileri A. Decreased ecto-5′nucleoti-dase activity of peripheral blood lymphocytes in human monoclonal gammopathies: correlation with tumor cell kinetics. Blood 1985; 65: 530–534
   PubMed Web of Science ®Google Scholar
• San Miguel J.F., Gonzalez M., Gascon A., Moro M.J., Hernandez J.M., Ortega F., Jimenez R., Guerras L., Romero M., Casanova F. Lymphoid subsets and prognostic factors in multiple myeloma. Cooperative Group for the Study of Monoclonal Gammopathies. Br. J. Haematol. 1992; 80: 305–309
   PubMed Web of Science ®Google Scholar
• Vacca A., Di Stefano R., Frassanito A., Lodice G., Dammacco F. A disturbance of the IL-2/IL-2 receptor system parallels the activity of multiple myeloma. Clin. Exp. Immunol. 1991; 84: 429–434
   PubMed Web of Science ®Google Scholar
• Cimino G., Avvisati G., Amadori S., Cava M.C., Giannarelli D., Di Nucci G.D., Magliocca V., Petrucci M.T., Poti G., Sgadari C. High serum IL-2 levels are predictive of prolonged survival in multiple myeloma. Br. J. Haematol. 1990; 75: 373–377
   PubMed Web of Science ®Google Scholar
• Bretscher P. The two-signal model of lymphocyte activation twenty-one years later. Immunol. Today 1992; 13: 74–76
   PubMedGoogle Scholar
• Raff M.C. Social controls on cell survival and cell death. Nature 1992; 356: 397–400
   PubMed Web of Science ®Google Scholar
• Uehara T., Miyawaki T., Ohta K., Tamaru Y., Yokoi T., Nakamura S., Taniguchi N. Apoptotic cell death of primed CD45R0+ T lymphocytes in Epstein-Barr virus-induced infectious mononucleosis. Blood 1992; 80: 452–458
   PubMed Web of Science ®Google Scholar
• Meyaard L., Otto S.A., Jonker R.R., Mijnster M.J., Keet R. P. M., Miedema F. Programmed death of T cells in HIV-1 infection. Science 1992; 257: 217–219
   PubMed Web of Science ®Google Scholar
• Truneh A., Albert F., Goldstein P., Schmitt-Verhulst A.M. Early steps of lymphocyte activation bypassed by synergy between calcium ionophores and phorbol ester. Nature 1985; 313: 318–320
   PubMed Web of Science ®Google Scholar
• Massaia M., Bianchi A., Attisano C., Peola S., Redoglia V., Dianzani U., Pileri A. Detection of hyperreactive T cells in multiple myeloma by multivalent cross-linking of the CD3/TCR complex. Blood 1991; 78: 1770–1780
   PubMed Web of Science ®Google Scholar
• June C.H., Fletcher M.C., Ledbetter J.A., Samelson L.E. Increases in tyrosine phopshorylation are detectable before phospholipase C activation after T cell receptor stimulation. J. Immunol. 1990; 144: 1591–1599
   PubMed Web of Science ®Google Scholar
• Massaia M., Perrin L., Bianchi A., Ruedi J., Attisano C., Altieri A., Rijkers G.T., Thompson L.F. Human T cell activation: synergy between CD73 (ecto-5′nucleotidase) and signals delivered through CD3 and CD2 molecules. J. Immunol. 1990; 145: 1664–1674
   PubMed Web of Science ®Google Scholar
• Yun Y.S., Hargrove M.E., Ting C.C. In vivo antitumor activity of anti-CD3-induced activated killer cells. Cancer Res. 1989; 49: 4770–4774
   PubMed Web of Science ®Google Scholar
• Anderson P.M., Blazar B.R., Bach F.H., Ochoa A.C. Anti-CD3 + IL-2-stimulated murine killer cells. In vitro generation and in vivo antitumor activity. J. Immunol. 1989; 142: 1383–1394
   PubMed Web of Science ®Google Scholar
• Gallinger S., Hoskin D.W., Mullen J. B. M., Wong A. H. C., Roder J.C. Comparison of cellular immunotherapies and anti-CD3 in the treatment of MCA 38-LD experimental hepatic metastases in C57BL/6 mice. Cancer Res. 1990; 50: 2476–2480
   PubMed Web of Science ®Google Scholar
• Yang S.C., Owen-Schaub L.B., Roth J.A., Grimm E.A. Characterization of OKT3-initiated lymphokine-activated effectors expanded with interleukin-2 and tumor necrosis factor-α. Cancer Res. 1990; 50: 3526–3532
   PubMed Web of Science ®Google Scholar
• Ellenhom J.D., Hirsch R., Schreiber H., Bluestone J.A. In vivo administration of anti-CD3 prevents malignant progressor tumor growth. Science 1988; 242: 569–571
   PubMed Web of Science ®Google Scholar
• Yoshizawa H., Chang A.E., Shu S. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J. Immunol. 1991; 147: 729–737
   PubMed Web of Science ®Google Scholar
• Schoof D.D., Selleck C.M., Massaro A.F., Jung S.E., Eberlein T.J. Activation of human tumor-infiltrating lymphocytes by monoclonal antibodies directed to the CD3 complex. Cancer Res. 1990; 50: 1138–1143
   PubMed Web of Science ®Google Scholar
• Crossland K.D., Lee V.K., Chen W., Riddell S.R., Greenberg P.D., Cheever M.A. T cells from tumor-immune mice nonspecifically expanded in vitro with anti-CD3 plus IL-2 retain specific function in vitro and eradicate disseminated leukemia in vivo. J. Immunol. 1991; 146: 4414–4420
   PubMed Web of Science ®Google Scholar
• Massaro A.F., Schoof D.D., Rubinstein A., Zuber M., Leonard-Vidal F.J., Eberlein T.J. Solid-phase anti-CD3 antibody activation of murine tumor-infiltrating lymphocytes. Cancer Res. 1990; 50: 2587–2592
   PubMed Web of Science ®Google Scholar
• Yoshizawa H., Sakai K., Chang A.E., Shu S. Activation by anti-CD3 of tumor-draining lymph node cells for specific adoptive immunotherapy. Cell. Immunol. 1991; 134: 473–479
   PubMed Web of Science ®Google Scholar
• Urba W.J., Ewel C., Kopp W., Smith J.W., Steis R.G., Ashwell J.D., Creekmore S.P., Rossio J., Sznol M., Sharfman W., Fenton R., Janik J., Watson T., Beveridge J., Longo D.L. Anti-CD3 monoclonal antibody treatment of patients with CD3-negative tumors: a phase IA/B study. Cancer Res. 1992; 52: 2394–2401
   PubMed Web of Science ®Google Scholar
• Massaia M., Bianchi A., Peola S., Borrione P., Attisano C., Pileri A. Sequential administration of OKT3 (anti-CD3) and interleukin-2 in two patients with chemoresistant hematological disease. Eur. J. Haematol. 1992; 49: 150–152
   PubMed Web of Science ®Google Scholar
• Curti B.D., Longo D.L., Ochoa A.C., Conlon K.C., Smith J.W., Alvord G., Creekmore S.P., Fenton R.G., Gause B.L., Holmlund J., Janik J.E., Ochoa J., Rice P.A., Sharfman W.H., Sznol M., Urba W.J. Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2. J. Clin. Oncol. 1993; 11: 652–660
   PubMed Web of Science ®Google Scholar
• Crabtree G.R. Contingent genetic regulatory events in T lymphocyte activation. Science 1989; 243: 355–361
   PubMed Web of Science ®Google Scholar
• Anderson K.C., Jones R.M., Morimoto C., Leavitt P., Barm B.A. Response patterns of purified myeloma cells to hematopoietic growth factors. Blood 1989; 73: 1915–1924
   PubMed Web of Science ®Google Scholar
• Zhang X.G., Klein B., Bataille R. Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood 1989; 74: 11–13
   PubMed Web of Science ®Google Scholar
• Zhang X.G., Bataille R., Jourdan M., Saeland S., Banchereau J., Mannoni P., Klein B. Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells. Blood 1990; 76: 2599–2605
   PubMed Web of Science ®Google Scholar
• Caligaris-Cappio F., Bergui L., Gregoretti M.G., Gaidano G.L., Gaboli M., Schena M., Zambonin Zallone A., Marchisio P.C. Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood 1991; 77: 2688–2693
   PubMed Web of Science ®Google Scholar
• Vernino L., McAnally L.M., Ramberg J., Lipsky P.E. Generation of nondividing high rate Ig-secreting plasma cells in cultures of human B cells stimulated with anti-CD3 activated T cells. J. Immunol. 1992; 148: 404–410
   PubMed Web of Science ®Google Scholar
• Massaia M., Attisano C., Peola S., Montacchini L., Omede P., Corradini P., Ferrero D., Boccadoro M., Bianchi A., Pileri A. Rapid generation of anti-plasma cell activity in the bone marrow of myeloma patients by CD3 cross-linking. Blood 1993; 82: 1787–1797
   PubMed Web of Science ®Google Scholar
• Charak B.S., Malloy B., Agah R., Mazumder A. A novel approach to purging of leukemia by activation of bone marrow with interleukin-2. Bone Marrow Transplant 1990; 6: 193–198
   PubMed Web of Science ®Google Scholar
• Van den Brink M. R. M., Voogt P.J., Marjit W. A. F., van Luxemburg-Heys S. A. P., van Rood J.J., Brand A. Lymphokine activated killer cells selectively kill tumor cells in bone marrow without compromising stem cell function in vitro. Blood 1989; 74: 254–360
   Google Scholar
• Weiden P.L., Sullivan K. ML, Flournoy N., Storb R., Thomas E.D. Antileukemic effect of chronic graft-versus-host disease. N. Engl. J. Med. 1981; 304: 1529–1531
   PubMed Web of Science ®Google Scholar
• Maraninchi D., Blaise D., Rio B., Leblond V., Dreyfus F., Gluckman E., Guyotat D., Pico J.L., Michallet M., Ifrah N., Bordigoni A. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukemias. Lancet 1987; II: 175–178
   Google Scholar
• Charak B.S., Brynes R.K., Groshen S., Chen S.C., Mazumder A. Bone marrow transplantation with interleukin-2-activated bone marrow followed by interleukin-2-therapy for acute myeloid leukemia in mice. Blood 1990; 76: 2187–2191
   PubMed Web of Science ®Google Scholar
• Gibson F.M., Malkovska V., Myint A.A., Meager A., Gordon-Smith E.C. Mechanism of suppression of normal hemopoietic activity by lymphokine-activated killer cells and their products. Exp. Hematol. 1991; 19: 659–663
   PubMed Web of Science ®Google Scholar
• Takahashi M., Oshimi K., Mizoguchi H. Inhibition of human granulocite-macrofage colony formation by interleukin-2-treated lymphocytes is mediated by interferon-γ and tumor necrosis factor-α. Exp. Hematol. 1990; 18: 395–399
   PubMed Web of Science ®Google Scholar
• Monaco A.P. Renal prophylaxis with Orthoclone OKT3 in the United States. Transplant. Proc 1989; 21(Suppl. 2)7–13
   Google Scholar
• Busuttil R.W. Use of Orthoclone OKT3 for prophylaxis in liver transplantation and its re-use in liver allograft rejection. Transplant. Proc 1989; 21(Suppl. 2)19–23
   Google Scholar
• Goldstein J.P., Primo G. Prophylaxis with OKT3 in high-risk heart transplant patients. Transplant. Proc 1989; 21(Suppl. 2)35–36
   PubMedGoogle Scholar
• Burke G.W., III, Vercellotti G.M., Simmons R.L., Howe R.B., Canafax D.M., Najarian J.S. Reversible pancytopenia following OKT3. Use in the contest of multidrug suppression for kidney allografting. Transplantation 1989; 48: 403–408
   PubMed Web of Science ®Google Scholar
• Notter M., Maurer J., Krackhardt A., Henkel B., Henze K., Bochert G., Ludwig W.D., Berdel W.E., Thiel E. Ex vivo elimination of chronic myeloid leukemia (CML) cells following activation and targeting of host T cells by combination of cytokines and CD3 monoclonal antibodies. Blood 1993; 82(suppl 1)975
   Google Scholar
• Abramowicz A., Schandene L., Goldman M., Crusiaux A., Vereerstraeten P., De Pauw L., Wybran J., Kinnaert P., Dupont E., Toussaint C. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989; 47: 606–608
   PubMed Web of Science ®Google Scholar
• Ferran C., Sheehan K., Dy M., Schreiber R., Merite S., Landais P., Noel L.H., Grau G., Bluestone J., Bach J.F., Chatenoud L. Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. Eur. J. Immunol. 1990; 20: 509–515
   PubMed Web of Science ®Google Scholar
• Ellenhorn J.D., Woodle E.S., Ghobreal I., Thistlewaite J.R., Bluestone J.A. Activation of human T cells in vivo following treatment of transplant recipients with OKT3. Transplantation 1990; 50: 608–612
   PubMed Web of Science ®Google Scholar
• Nishimura T., Nakamura Y., Takeuchi Y., Tokuda Y., Iwasawa M., Kawasaki A., Okumura K., Habu S. Generation, propagation, and targeting of human CD4+ helper/killer T cell induced by anti-CD3 monoclonal antibody plus recombinant IL-2. J. Immunol. 1992; 148: 285–291
   PubMed Web of Science ®Google Scholar
• Yannelli J.R., Crumpacker D.B., Good R.W., Friddell C.D., Poston R., Horton S., Maleckar J.R., Oldham R.K. Use of anti-CD3 monoclonal antibody in the generation of effector cells from human solid tumors for use in cancer biotherapy. J. Immunol. Methods 1990; 1: 91–94
   Web of Science ®Google Scholar
• Attisano C., Bianchi A., Montacchini L., Carlesso N., Peola S., Bruno B., Roux V., Ferrero D., Gallo E., Boccadoro M., Pileri A., Massaia M. Generation of anti-tumour activity by OKT3-stimulation in multiple myeloma: in vitro inhibition of autologous haemopoiesis. Brit. J. Haematol. 1994; 87, in press
   PubMed Web of Science ®Google Scholar